· Scientific publication
Final NEOTORCH analysis presented at the ESMO Congress 2026
The final analysis of the Phase 3 NEOTORCH trial was presented at the ESMO Congress 2026 and published in Annals of Oncology.
The study evaluated perioperative toripalimab plus chemotherapy in patients with resectable stage II or III non-small cell lung cancer.
Read the full company release